OBJECTIVE: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors known to produce and secrete high levels of circulating catecholamines and their metabolites. The biochemical characteristics of these tumors can be used to divide them into three major phenotypes. The adrenergic, noradrenergic and dopaminergic phenotypes are defined by predominant elevations in epinephrine and metanephrine, norepinephrine and normetanephrine, and dopamine and 3-methoxytyramine, respectively. There are over 15 well-identified tumor-susceptibility genes responsible for approximately 40% of the cases. The objective of this review article is to outline specific genotype/biochemical phenotype relationships. METHODS: Literature review. RESULTS: None. CONCLUSION: Biochemical phenotype of PPGL is determined by the underlying genetic mutation and the associated molecular pathway. Identification of genotype/biochemical relationships is valuable in prioritizing testing for specific genes, making treatment decisions and monitoring disease progression. ABBREVIATIONS: 3-MT = 3-methoxytyramine; EPAS1 = endothelial pas domain protein 1; FH = fumarate hydratase; HIF2A = hypoxia inducible factor type 2A; MEN2 = multiple endocrine neoplasia type 2; NF1 = neurofibromatosis type 1; PNMT = phenylethanolamine N-methyltransferase; PPGL = pheochromocytoma and paraganglioma; RET = rearranged during transfection; SDH = succinate dehydrogenase; SDHAF2 = succinate dehydrogenase complex assembly factor 2; TCA = tricarboxylic acid; TH = tyrosine hydroxylase; TMEM127 = transmembrane protein 127; VHL = von Hippel-Lindau.
OBJECTIVE:Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors known to produce and secrete high levels of circulating catecholamines and their metabolites. The biochemical characteristics of these tumors can be used to divide them into three major phenotypes. The adrenergic, noradrenergic and dopaminergic phenotypes are defined by predominant elevations in epinephrine and metanephrine, norepinephrine and normetanephrine, and dopamine and 3-methoxytyramine, respectively. There are over 15 well-identified tumor-susceptibility genes responsible for approximately 40% of the cases. The objective of this review article is to outline specific genotype/biochemical phenotype relationships. METHODS: Literature review. RESULTS: None. CONCLUSION: Biochemical phenotype of PPGL is determined by the underlying genetic mutation and the associated molecular pathway. Identification of genotype/biochemical relationships is valuable in prioritizing testing for specific genes, making treatment decisions and monitoring disease progression. ABBREVIATIONS: 3-MT = 3-methoxytyramine; EPAS1 = endothelial pas domain protein 1; FH = fumarate hydratase; HIF2A = hypoxia inducible factor type 2A; MEN2 = multiple endocrine neoplasia type 2; NF1 = neurofibromatosis type 1; PNMT = phenylethanolamine N-methyltransferase; PPGL = pheochromocytoma and paraganglioma; RET = rearranged during transfection; SDH = succinate dehydrogenase; SDHAF2 = succinate dehydrogenase complex assembly factor 2; TCA = tricarboxylic acid; TH = tyrosine hydroxylase; TMEM127 = transmembrane protein 127; VHL = von Hippel-Lindau.
Authors: Jacques W M Lenders; Karel Pacak; McClellan M Walther; W Marston Linehan; Massimo Mannelli; Peter Friberg; Harry R Keiser; David S Goldstein; Graeme Eisenhofer Journal: JAMA Date: 2002-03-20 Impact factor: 56.272
Authors: Henricus P M Kunst; Martijn H Rutten; Jan-Pieter de Mönnink; Lies H Hoefsloot; Henri J L M Timmers; Henri A M Marres; Jeroen C Jansen; Hannie Kremer; Jean-Pierre Bayley; Cor W R J Cremers Journal: Clin Cancer Res Date: 2011-01-11 Impact factor: 12.531
Authors: G Eisenhofer; H Keiser; P Friberg; E Mezey; T T Huynh; B Hiremagalur; T Ellingson; S Duddempudi; A Eijsbouts; J W Lenders Journal: J Clin Endocrinol Metab Date: 1998-06 Impact factor: 5.958
Authors: Matthew A Nazari; Jared S Rosenblum; Mark C Haigney; Douglas R Rosing; Karel Pacak Journal: J Am Coll Cardiol Date: 2020-07-28 Impact factor: 24.094
Authors: Edward P Lin; Bennett B Chin; Lauren Fishbein; Toshio Moritani; Simone P Montoya; Shehanaz Ellika; Shawn Newlands Journal: Radiol Imaging Cancer Date: 2022-05
Authors: Lauren N Krumeich; Andrew J Cucchiara; Katherine L Nathanson; Rachel R Kelz; Lauren Fishbein; Douglas L Fraker; Robert E Roses; Debbie L Cohen; Heather Wachtel Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 6.134
Authors: Annika M A Berends; Graeme Eisenhofer; Lauren Fishbein; Anouk N A V D Horst-Schrivers; Ido P Kema; Thera P Links; Jacques W M Lenders; Michiel N Kerstens Journal: Cancers (Basel) Date: 2019-08-06 Impact factor: 6.639
Authors: Bernardo Dias Pereira; Tiago Nunes da Silva; Ana Teresa Bernardo; Rui César; Henrique Vara Luiz; Karel Pacak; Luísa Mota-Vieira Journal: Int J Endocrinol Date: 2018-03-20 Impact factor: 3.257